NATCOPHARM vs SPARC: Stock Comparison
NATCO PHARMA is the larger company by market capitalisation. NATCO PHARMA shows a higher dividend yield and lower leverage, while SUN PHARMA ADV.RES.CO.LTD shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
NATCOPHARM leads 4; SPARC leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NATCOPHARM | SPARC |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | NATCOPHARM | SPARC |
|---|---|---|
| Live Price | ₹785.65 | ₹178.55 |
| Day Change | -0.24% | -2.42% |
| Volume | 1.63 L | 1.93 L |
| 52-Week High | ₹1,226.8 | ₹289 |
| 52-Week Low | ₹773.6 | ₹108 |
| Distance from 52W High | -35.96% | -38.22% |
Valuation
| Metric | NATCOPHARM | SPARC |
|---|---|---|
| Market Cap | ₹15,403 Cr | ₹5,793 Cr |
| P/E Ratio | 13.49x | 3.75x |
| P/B Ratio | 1.67x | 4.44x |
| EPS | ₹10.53 | ₹-0.64 |
| Book Value | ₹470.06 | ₹41.26 |
| Dividend Yield | 0.57% | 0% |
Growth
| Metric | NATCOPHARM | SPARC |
|---|---|---|
| Revenue Growth (TTM YoY) | -39.6% | 6,716.8% |
| EPS Growth (TTM YoY) | -34.1% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | NATCOPHARM | SPARC |
|---|---|---|
| ROE | 14.98% | 116.01% |
| ROCE | 15.1% | 83.81% |
| Net Margin | 34.78% | 82.65% |
| Operating Margin | 38.85% | 84.46% |
| Debt to Equity | 0.08x | 0.42x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | NATCOPHARM | SPARC |
|---|---|---|
| Promoter Holding | 49.12%▼ 0.02 pp | 65.67% |
| FII Holding | 16%▼ 0.99 pp | 3.75%▼ 0.15 pp |
| DII Holding | 6.16%▲ 0.54 pp | 0.11%▲ 0.02 pp |
| Public Holding | 28.45%▲ 0.48 pp | 30.48%▲ 0.15 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NATCO PHARMA and SUN PHARMA ADV.RES.CO.LTD.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.